Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents
Brief Summary: This is a Phase III, multicenter, randomized, double-blind, stratified, parallel-group study with three active comparators in subjects with moderate to severe persistent asthma. The study consists of a run-in period of 4 weeks, followed by a treatment period of 12 weeks, and a follow up contact period of one week. The total duration of the study is 17 weeks. 990 subjects will be randomized to one of three treatments (FF/VI Inhalation Powder 200/25 mcg once daily in the evening; FF/VI Inhalation Powder 100/25 mcg once daily in the evening; FF 100 Inhalation Powder once daily in the evening) for 12 weeks. In addition, all subjects will be supplied albuterol/salbutamol inhalation aerosol at Visit 1 to use as needed for acute asthma symptoms throughout the entire study. Subjects will attend four on-treatment visits at Weeks 2, 4, 8, and 12 (Visits 4 through 7).


Options:
A: Arm Label: Fluticasone Furoate/Vilanterol 100/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler, Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler | Arm Label: Fluticasone Propionate/Salmeterol 250/50 mcg; Type: EXPERIMENTAL; Interventions: Drug: Placebo inhalation powders via ELLIPTA inhaler, Drug: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler | Arm Label: Fluticasone Propionate 250 mcg; Type: EXPERIMENTAL; Interventions: Drug: Placebo inhalation powders via ELLIPTA inhaler, Drug: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler; Assigned to Arm(s): Fluticasone Furoate/Vilanterol 100/25 mcg | Intervention Type: DRUG; Name: Placebo inhalation powders via ELLIPTA inhaler; Assigned to Arm(s): Fluticasone Propionate 250 mcg, Fluticasone Propionate/Salmeterol 250/50 mcg | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler; Assigned to Arm(s): Fluticasone Propionate/Salmeterol 250/50 mcg | Intervention Type: DRUG; Name: Placebo inhalation powder via ACCUHALER/DISKUS inhaler; Assigned to Arm(s): Fluticasone Furoate/Vilanterol 100/25 mcg | Intervention Type: DRUG; Name: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler; Assigned to Arm(s): Fluticasone Propionate 250 mcg
B: Arm Label: Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Vilanterol, Drug: Placebo Inhalation Powder Diskus | Arm Label: Salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol Inhalation Powder, Drug: Placebo Inhalation Powder NDPI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhalation Powder NDPI, Drug: Placebo Inhalation Powder Diskus | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Vilanterol | Intervention Type: DRUG; Name: Salmeterol Inhalation Powder; Assigned to Arm(s): Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder NDPI; Assigned to Arm(s): Placebo, Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder Diskus; Assigned to Arm(s): Placebo, Vilanterol
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo Respimat | Arm Label: tiotropium low dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium Respimat low dose | Arm Label: tiotropium high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium Respimat high dose | Intervention Type: DRUG; Name: tiotropium Respimat low dose; Assigned to Arm(s): tiotropium low dose | Intervention Type: DRUG; Name: placebo Respimat; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: tiotropium Respimat high dose; Assigned to Arm(s): tiotropium high dose
D: Arm Label: Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/ Vilanterol 200/25 mcg | Arm Label: Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/ Vilanterol 100/25 mcg | Arm Label: Arm 3: Fluticasone Furoate 100 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate 100 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate/ Vilanterol 200/25 mcg; Assigned to Arm(s): Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate/ Vilanterol 100/25 mcg; Assigned to Arm(s): Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate 100 mcg; Assigned to Arm(s): Arm 3: Fluticasone Furoate 100 mcg

Answer: D